Omega-3 EPA·DHA and
Senior Cardiovascular Health:
Benefits and Limits from
2024–2025 Clinical Trials
Cardiovascular disease is the leading cause of death among adults over 60. As blood vessels age, chronic low-grade inflammation accumulates, arterial plaques build up, and the risks of heart attack and stroke climb. The nutrient most studied over decades for slowing this "vascular aging" is omega-3 fatty acids — EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
The latest clinical trials, however, paint a far more nuanced picture than the familiar "fish oil is good for you" narrative. The RESPECT-EPA trial published in Circulation in 2024 and large-scale meta-analyses involving hundreds of thousands of patients make clear that "which form, how much, and for whom" is what determines outcomes. This article synthesizes the key data published between 2024 and 2025 to map out omega-3's benefits and limitations — and what that means in practice for seniors.
PART 1 · Molecular Mechanisms: How Omega-3 Protects Blood Vessels
1-1. Not Just Fat — Signal Molecules
EPA and DHA integrate into the phospholipid bilayer of cell membranes, increasing membrane fluidity and optimizing receptor function. But the function attracting the most attention in 2024–2025 research is their role as precursors to Specialized Pro-resolving Mediators (SPMs) — a class of bioactive lipids that actively resolve inflammation. SPMs include Resolvins, Protectins, and Maresins.
Resolvins
E-series synthesized from EPA; D-series from DHA. They halt excessive neutrophil recruitment and promote efferocytosis — the clearance of cellular debris at inflammation sites — actively resolving inflammation rather than merely suppressing it.
Protectins
Derived from DHA. Particularly involved in protecting neural tissue and the retina. They suppress neuroinflammation and regulate apoptosis, shielding brain and retinal cells from oxidative stress.
Maresins
Synthesized by macrophages from DHA. They promote tissue regeneration and modulate pain signaling. 2024 research also reports maresins contribute to improved insulin sensitivity.
Triglyceride Reduction
EPA and DHA suppress hepatic VLDL synthesis and promote fatty acid β-oxidation, reducing blood triglycerides (TG) by up to 20–30%. The effect is most pronounced at high doses (4 g/day).
1-2. Why Omega-3 Becomes More Important With Age
"Inflammaging" refers to the chronic low-grade systemic inflammation that accumulates as we age. In adults over 65, inflammatory markers such as TNF-α, IL-6, and CRP remain persistently elevated compared to younger adults — directly linked to increased risk of cardiovascular disease, cognitive decline, sarcopenia, and cancer. The SPMs generated from omega-3 are molecular tools that actively resolve this inflammaging state. Research published in 2024–2025 has begun using circulating SPM levels as a biomarker of omega-3 status — reflecting a paradigm shift from "did the person take omega-3?" to "is the body actually mounting an anti-inflammatory response?"
PART 2 · Key Clinical Trial Data: 2024–2025
2-1. RESPECT-EPA — Published in Circulation, 2024
The RESPECT-EPA trial, published in Circulation in June 2024, was a randomized, double-blind, controlled trial administering pure EPA (icosapentaenoic acid) 1,800 mg/day to 2,506 patients with stable coronary artery disease across 95 Japanese centers over a median 5-year follow-up. Forty-two percent of participants were 70 or older; all were selected for low baseline EPA/AA (arachidonic acid) ratios, identifying them as high-risk.
RESPECT-EPA 2024 Key Results (Circulation)
· Participants: 2,506 | 95 Japanese centers | 42% aged 70+
· Intervention: Pure EPA 1,800 mg/day vs. control (no treatment)
· Follow-up: Median 5 years
· Primary composite endpoint (CV death, non-fatal MI, non-fatal stroke, unstable angina, coronary revascularization): EPA 9.1% vs. control 12.6% — HR 0.79 (p=0.055, borderline significance)
· Secondary endpoint (sudden death, fatal/non-fatal MI, unstable angina, revascularization): EPA 6.6% vs. control 9.7% — HR 0.73 (p<0.05) — 25% significant risk reduction
· Caution: New-onset atrial fibrillation was significantly higher in the EPA group
· Source: Nishizaki Y et al., Circulation 2024;150:103–113
2-2. REDUCE-IT vs. STRENGTH — The Placebo Controversy
REDUCE-IT (2018) — a large trial of 8,179 patients receiving pure EPA (icosapent ethyl, 4 g/day) — made waves by reducing major adverse cardiovascular events (MACE) by 25%. By contrast, STRENGTH (2020), which tested a combined EPA+DHA omega-3 at 4 g/day in ~13,000 patients, showed no significant difference in MACE (12.0% vs. 12.2%).
A 2024 reanalysis published in Frontiers in Nutrition (PMC11697285) conducted a precise comparison of the two trials' key differences. REDUCE-IT's mineral oil placebo may have inflated apparent treatment benefits by raising control-group hsCRP by 32%, while STRENGTH's corn oil placebo may have had mild cardioprotective effects of its own. This suggests that the distinction between "pure EPA" and "EPA+DHA blend" formulations may meaningfully affect outcomes.
2-3. Meta-Analysis of 18 RCTs, 134,144 Patients (2024)
A 2024 meta-analysis of 18 RCTs involving 134,144 patients, published in the European Journal of Preventive Cardiology, confirmed that omega-3 supplementation significantly reduces coronary revascularization, myocardial infarction, and cardiovascular mortality in statin-treated patients. Notably, the analysis concluded that EPA monotherapy produced significantly greater cardiovascular protection than EPA+DHA combination therapy.
PART 3 · Form Matters — Triglyceride vs. Ethyl Ester Bioavailability
3-1. The Two Main Forms
Omega-3 supplements sold in pharmacies and health stores come in two primary forms. Ethyl ester (EE) form is produced during the concentration process when EPA and DHA are bound to ethanol rather than a glycerol backbone — a structure that does not occur naturally. Triglyceride (TG) form most closely resembles the molecular structure found in nature. Re-esterified triglyceride (rTG) is a premium product that converts EE back into TG form.
| Property | Triglyceride Form (TG/rTG) | Ethyl Ester Form (EE) |
|---|---|---|
| Similarity to natural state | High — identical to fish fat structure | Low — structure not found in nature |
| Short-term absorption | 48% higher EPA, 36% higher DHA vs. EE | Lower than TG form |
| Fasted absorption | Stable regardless of meal timing | Drops to ~20% when taken fasted |
| Absorption after high-fat meal | High | Rises to ~60% (must be taken with food) |
| Long-term (3+ months) difference | No statistically significant difference between forms in long-term studies | |
| Cost | Higher | Lower |
3-2. What Matters Most for Seniors
In long-term studies (3+ months), blood EPA and DHA levels do not differ significantly between TG and EE forms. However, for seniors with declining digestive function, aligning supplement choice with eating habits is more important. EE form must be taken with a fat-containing meal; TG and rTG forms absorb reliably regardless of meal timing, improving adherence. Notably, both REDUCE-IT (EE) and RESPECT-EPA (EE-like formulation) were designed to be taken with food.
PART 4 · Atrial Fibrillation Risk — What Every Senior Must Know
4-1. The Dose-Dependent AF Signal
A 2025 meta-analysis of 34 RCTs involving 114,326 individuals (medRxiv, 2025) concluded that high-dose omega-3 supplementation raises atrial fibrillation (AF) risk in a dose-dependent manner. This is especially important for seniors over 65. AF is an arrhythmia that multiplies stroke risk fivefold; seniors with a history of AF should use high-dose omega-3 only under close cardiology supervision.
⚠ Omega-3 and Atrial Fibrillation Risk — 34 RCTs, 114,326 Participants (2025)
· Omega-3 overall: relative risk of AF increased by 24%
· ~1,000 mg/day low dose: AF risk ~12% higher
· 1,800–4,000 mg/day high dose: AF risk ~50% higher
· RESPECT-EPA (1,800 mg): new-onset AF significantly higher than control
Key message: High-dose omega-3 supplements (≥2,000 mg/day) must only be used after consultation with a cardiologist. Seniors with AF history, heart failure, or anticoagulant therapy require particular caution.
4-2. Is There AF Risk From Dietary Fish?
Importantly, the observed AF risk increase is specific to high-concentration supplements — the same risk has not been reported with natural consumption of oily fish such as salmon, mackerel, or sardines. Eating oily fish 2–3 times per week remains beneficial for cardiovascular health according to the consensus of 2024–2025 nutrition guidelines. The American Heart Association (AHA) recommends prioritizing food sources over supplements for people without existing cardiovascular disease.
PART 5 · Evidence-Based Practice Guide for Seniors
5-1. Who Benefits Most From Supplements?
Synthesizing 2024–2025 data, the clearest cardiovascular benefit from omega-3 supplements has been demonstrated in: ① patients with established cardiovascular disease on statin therapy; ② high-risk individuals with elevated blood triglycerides; ③ East Asian older adults with low EPA/AA ratios. For primary prevention in healthy adults, evidence is inconsistent — the VITAL trial (25,871 participants) found no significant MACE reduction with 840 mg/day.
| Population | Recommended Approach | Evidence |
|---|---|---|
| Healthy seniors (primary prevention) | Prioritize oily fish 2–3×/week over supplements | AHA 2024 Guidelines; VITAL trial |
| Diagnosed cardiovascular disease | Consider high-dose EPA monotherapy after cardiologist consultation | RESPECT-EPA 2024; REDUCE-IT |
| Hypertriglyceridemia | Prescription EPA (4 g/day) or physician-directed rTG form | Meta-analysis (134,144 pts, 2024) |
| History of atrial fibrillation | High-dose supplements contraindicated — physician consultation required | 114,326-person meta-analysis (2025) |
| Anticoagulant users | Possible increased bleeding risk — dose adjustment essential | Drug interaction profile |
🐟 Omega-3 Practice Guide for Seniors
- Prioritize oily fish (salmon, mackerel, sardines, saury) 2–3 times per week over supplements. One serving (100 g) contains approximately 1,000–2,000 mg EPA+DHA.
- If supplementing, choose TG or rTG form and always take with a meal. EE form must be accompanied by a fat-containing meal for adequate absorption.
- Consult a cardiologist before taking high-dose supplements (≥2,000 mg/day) — especially those with AF history or bleeding disorders.
- Always inform your doctor if taking anticoagulants (warfarin, apixaban) or antiplatelet agents (aspirin, clopidogrel) alongside omega-3.
- Plant-based omega-3 (ALA) from EVOO, flaxseed, and walnuts also helps diversify SPM synthesis substrates.
- Monitor triglyceride levels regularly — if above 150 mg/dL, discuss omega-3 therapy with your physician.
References (Evidence-Based · PubMed Verified)
- Nishizaki Y, et al. "Icosapentaenoic Acid for Prevention of Cardiovascular Events in Patients With Prior Coronary Artery Disease and Low Eicosapentaenoic Acid/Arachidonic Acid Ratio (RESPECT-EPA)." Circulation. 2024;150:103–113.
- Bhatt DL, et al. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT)." N Engl J Med. 2019;380:11–22.
- Nicholls SJ, et al. "Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (STRENGTH)." JAMA. 2020;324(22):2268–2280.
- Yan W, et al. "Unraveling the discrepancies between REDUCE-IT and STRENGTH: a critical analysis of trial design, placebo effects, and omega-3 fatty acid formulations." Frontiers in Nutrition. 2024;11. PMC11697285.
- Gencer B, et al. "Omega-3 Fatty Acids and Outcomes in Patients with Prior Coronary Heart Disease." European Journal of Preventive Cardiology. 2024;31(15):1863–1872. (18 RCTs, 134,144 participants)
- Lombardi M, et al. "Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials." medRxiv. 2025. (34 RCTs, 114,326 individuals)
- Manson JE, et al. "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL)." N Engl J Med. 2019;380:23–32.
- Dyerberg J, et al. "Bioavailability of marine n-3 fatty acid formulations." Prostaglandins Leukot Essent Fatty Acids. 2010;83(3):137–141.
- Wakimoto K, et al. "Absorption of EPA and DHA: triglyceride vs ethyl ester forms." Lipids. 2024. PMC11012042.
- Serhan CN. "Pro-resolving lipid mediators are leads for resolution physiology." Nature. 2014;510:92–101.